Positive Oncology Data Meets an Older-Drug Problem
Bristol-Myers Squibb Company (NYSE:BMY) reported positive data from its radiopharmaceutical RYZ101 Phase III ACTION-1 trial and additional progress across multiple myeloma in October. These developments broaden potential sources of revenue, but the valuation question is whether new medicines can scale fast enough to replace sales that will face patent and generic pressure.
On October 12, 2026, Bristol-Myers Squibb Company reported that ACTION-1 met its primary endpoint for progression-free survival in certain advanced gastrointestinal and pancreatic neuroendocrine tumors. It is an important clinical step, not yet an approved product or quantified revenue stream. Investors must also consider launch timing, treatment economics, and the cost of a specialized radiopharmaceutical supply chain.
Bristol-Myers Squibb Company ranks ninth among the 11 best cancer stocks to invest in now, based on Q2 hedge fund holders. Which eight stocks attracted broader institutional interest, and how much oncology cash flow do they already generate compared with Bristol Myers?
The Growth Portfolio Is Expanding, but Must Replace Billions
The second-quarter results explain why the pipeline matters. Revenue grew about 6% to $12.97 billion, and the Growth Portfolio generated $7.6 billion, up 15% and already close to three-fifths of total sales. Reblozyl increased 29%, Breyanzi rose 41%, and Camzyos grew 59% to $416 million. The commercial replacement effort is underway, but the Legacy Portfolio still declined 4% amid generic pressure.
Bristol-Myers Squibb Company lifted 2026 guidance to roughly $49 billion-$50 billion in revenue and $6.75-$7.00 in non-GAAP EPS. Stronger new-drug sales support that outlook, but clinical results for medicines not yet launched should not be added mechanically to near-term forecasts.
The myeloma program offers a concrete example of what is at stake. The Phase III EXCALIBER-RRMM trial reported improved minimal residual disease-negative complete response results for Zenbexus-based treatment. Our analysis of the multiple-myeloma trial’s clinical and commercial implications examines why a promising endpoint is only one step toward replacing revenue. Separately, the arlo-cel CAR-T program could expand treatment options, but manufacturing scale and competition are important variables.
A Low P/E Can Be a Warning Rather Than a Bargain
The October 19 Seeking Alpha data places Bristol-Myers Squibb Company at 13.15 times trailing GAAP earnings and 11.09 times forward GAAP earnings, against sector medians of 26.46 and 24.59 times. Its forward non-GAAP multiple is 9.03 times, less than half the sector median of 19.13 and the company’s five-year average of 18.41. Forward EV/EBITDA is 8.50 times against 12.97 for the sector.
What matters is whether those denominators are sustainable. Consensus EPS growth is estimated at 7.65% for 2026 and just 0.03% for 2027, followed by declines of 16.73% in 2028 and 9.21% in 2029. The implied annual P/E correspondingly rises from approximately 9.02 times 2027 earnings to 10.83 times for 2028 and 11.93 for 2029. In other words, an apparently low near-term multiple coexists with forecasts of lower later-year profits.
The company’s valuation also shows approximately $45.05 billion of debt against $11.07 billion of cash. The debt load does not establish distress, but it raises the value of dependable operating cash generation during a period requiring both portfolio rebuilding and shareholder distributions.
Clinical Wins Have Uneven Earnings Implications
Not every positive trial materially changes valuation. The Phase III ALOFT-IPF study of non-oncology drug admilparant met its primary endpoint at 60 mg but not at 120 mg. Jefferies raised its target to $76 from $73 on October 13 and increased its peak sales estimate for the therapy to $2.4 billion from $680 million, while RBC Capital called the dose-response picture encouraging but confounding. These are divergent analyst interpretations, not established commercial outcomes.
Wells Fargo lowered its target to $60 from $65 on October 13 and retained Equal Weight, while Jefferies maintained Buy. Such differing assumptions reflect uncertainty over the pace and commercial value of the company’s pipeline. Our review of Bristol Myers’ CAR-T growth platform explores why oncology diversification requires more than a string of positive data releases.
Insider Monkey tracked 74 hedge funds holding Bristol-Myers Squibb Company in Q2, down from 83 in Q1. Shares short increased to 45.85 million on September 30 from 44.07 million in August, equal to 2.25% of float.
The investment test is ultimately replacement economics: how much revenue and margin can newer cancer therapies contribute before established products erode? A low earnings multiple offers some valuation restraint, but sustained value depends on successful commercialization rather than approvals or pipeline size alone.
READ NEXT: Bristol Myers’ Newer-Drug Growth Outlook and Merck’s Cancer-Drug Patent-Cliff Challenge.
Hedge Fund Resource Center